Permselective acrylic membranes were employed to prevent une rejection of discordant islet xenografts isolated from various large animals. Canine, porcine, and bovine islets were seeded into tubular diffusio abers and transplanted into the peritoneum of 27 nmmunosup pressed streptozotocin-induced diabetic Lewis rats. Si recipients received islet grafts from bovine calves, 7 receIved grafts from pigs, and 14 received grafts from dogs. Four of the latter were removed at 1 month. In the control group of 10 diabetic rats, 4 received nonencapsulted canine islets, 3 received nonencapsulated bovine islets, and 3 received nonencapated porcine islets. Recipients of encapsulated Islets promptly dropped from a pretranpaotation plasma glucose level of 487 ± 36 (mean ± SEM) to 84 ± 2 (canine), 81 ± 4 (bovine), and 81 ± 3 mg/dl (porcine) during the first week. 411 of the animals sustained theqe levels for at least 1 month. One rat taneously reverted to diabetes at 54 days taton; 4 other rats became hyperglycemic (glucose, >600 mg/di) after membrane removal on day 30. The rem 22 rats maintained fasting euglycema for >10 weeks. In contrast, rats that received Encapsulated Islets became hyperglycemic in <7 days. Intravenous glucose tolerance test K values (decline in glucose levels, %/min) at 1 month for the canine and bovine encapsulatedislet tr ant group were 3.5 ± 0.3 and 3.3 ± 0.1 compared with 3.3 ± 0.1 (P = 0.63) and 0.91 ± 0.1 (P < 0.0001) for normal (n = 4) and diabetic (n = 4) control groups. Morphologic studies of long-term functioning grafts (30-130 days) revealed well-preserved a, (3, and 8 (6) and pig (7) could enable the use of readily available supplies of large-animal donor tissue for islet grafting into human diabetics. Unfortunately, there is currently no clinically applicable immunologic method available that prevents the destruction of discordant islet xenografts (8) (9) (10) (11) .
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Diabetes afflicts an estimated 80 million people worldwide (1) . Even with improved procurement ofhuman organs, the supply of donor tissue would remain quite inadequate if pancreatic islet transplantation were to be developed as an effective therapy. One potential solution to this problem is the use of non-human donor islets. However, the transplantation of xenogeneic tissues of widely divergent species is difficult due to vigorous humoral and cellular immune responses. The most encouraging experience involves the encapsulation of donor islets in artificial membranes' that are impermeable to immunocytes and immunoglobulins but that permit crossover of lower molecular weight substances such as glucose and insulin (2, 3) . Preliminary studies in rodents have demonstrated that xenografted encapsulated islets can function for up to 210 days (4) . Although these experiments have proven Successful for closely related islet xenografts (concordant, rodent-to-rodent combinations), islet xenografts between discordant species add another dimension to the rejection response, in that most discordant species have natural cytotoxic antibodies against each other (5) . The development of successful islet isolation techniques for animals such as the cow (6) and pig (7) could enable the use of readily available supplies of large-animal donor tissue for islet grafting into human diabetics. Unfortunately, there is currently no clinically applicable immunologic method available that prevents the destruction of discordant islet xenografts (8) (9) (10) (11) .
Encouraged by the results obtained with the encapsulation of allogeneic and xenogeneic rodent islets in capillary hollow fibers (4, (12) (13) (14) , we sought to determine whether larger tubular membrane diffusion chambers (fabricated from XM-50 acrylic copolymer) can protect xenografts of canine, bovine, and porcine islets from rejection in the absence ofany immunosuppressive drugs. Because the formation of fibrous tissue around the membrane has been a cause offailure in the past, a smooth external skin was used to minimize this host reaction. (16) . The flow rate was 0.5 ml/min and the perifusate was collected with a microfraction collector (Gilson model 203). The samples were frozen for subsequent insulin assay using a standard equilibrium radioimmunoassay protocol as previously described (17) . The limit of assay sensitivity was 25 microunits (1 ng)/ml and data reduction was done by a log-logit transformation of the standard curve by COBRA y counter (Packard Instruments).
MATERIALS AND METHODS
Experimental Design. Recipient rats were anesthetized with ether inhalation. Free or macroencapsulated islets (1-2 x 104 islet equivalents) were introduced into the peritoneal cavity through a small (1-2 cm) midline incision. The wound was closed in two layers with 4-0 silk suture. In the experimental group of 27 rats, 6 received islet grafts from bovine calves, 7 received grafts from pigs, and the remaining 14 received grafts from dogs. Four of the latter were removed at 1 month. In the control group of 10 diabetic rats implanted with nonencapsulated islets, 4 received canine islets, 3 received bovine islets, and the remaining 3 received porcine islets. Intravenous glucose tolerance tests (IVGTTs) were performed at 1 month after transplantation and compared with normal (n = 4) and untreated diabetic (n -4) rats. Fifty percent (wt/vol) glucose (0.5 g/kg of body weight) was injected into the tail vein, and plasma glucose concentrations were measured at 0, 1, 5, 10, 20, 30, 40, 50, and 60 min after the glucose injection. K values (decline in glucose levels, %/min) were calculated according to standard methods (18) .
Histology. The islet implants and the pancreas of recipient animals were fixed in Bouin's solution, dehydrated, and embedded in paraffin. Five-micron sections were prepared and stained with hematoxylin/eosin and for the presence of insulin, glucagon, and somatostatin using immunoperoxidase techniques (19) . Two Fig. 1 . An =4-fold average increase from the basal insulin secretion was observed in both groups. The secretory response of the macroencapsulated islets was sustained for 60 min of glucose stimulation (300 mg/dl) and returned to basal levels after perifusion with the low-glucose solution (100 mg/dl). Five separate experiments in which this protocol was used indicated a delay of 7 ± 1 min before insulin concentration in the perfusate began to increase. This finding indicates that the islets encapsulated by this procedure were functionally intact and could respond rapidly to an increase in glucose concentration. Transplantation. Intraperitoneal transplants of 1-2 x 104 encapsulated islets reversed the diabetic state of all 27 recipient rats within 24 hr (Figs. 2-4 ). Plasma glucose levels (Q ± SEM) dropped from a pretransplantation level of 487 + 36 to 84 ± 2 (canine), 81 ± 4 (bovine), and 81 ± 3 mg/dl (porcine) during the first week. All of the animals sustained these levels for at least 1 month. One rat subsequently reverted to diabetes at 54 days posttransplantation and four canine islet xenograft recipients reverted to diabetes after membrane removal on day 30. The remaining 22 rats maintained fasting euglycemia for >10 weeks. In contrast, nonencapsulated islet transplants only partially reversed the diabetic state of the recipients, with-hyperglycemia returning to pretransplantation levels after 6-7 postoperative days (Figs. 2-4 Insets).
Metabolic Studies. The results of IVGTTs on normal control and transplanted rats are shown in Table 1 . Glucose clearance (K) rates of the animals transplanted with encapsulated islets were not statistically different from those of normal rats after the administration of-glucose (P = 0.63). However, the IVGTT profiles were not totally normal, although plasma glucose declined promptly, reaching nearnormal levels after 60 min and resulting in K values of 3.5 + 0.3 (canine islets), 3 .3 ± 0.1 (bovine islets), and 3.3 ± 0.1 (normal). By contrast, the untreated streptozotocin diabetic rats remained significantly hyperglycemic after glucose challenge, with K values imipaired at 0.91 ± 0.1 (P < 0.0001).
Histogy and Memborae Removal. To check for evidence against spontaneous recovery by (3 cells, pancreata from the experimental and control groups were routinely fixed and processed. The histological appearance is shown in Fig. 5 (Fig. 6) . The implanted membranes were generally free floating and free of cellular overgrowth. The external surfaces were free of fibrosis and host cell adherence. On microscopic examination, the membranes contained up to 85-900% viable islets. Immunohistochemical staining of the islets revealed hormone-producing cells, with varying degrees of a, A, and 8 granulation (Fig. 7) .
DISCUSSION
Transplantation of islets across a wide species barrier has been difficult to achieve. Islets isolated from large mammals and humans and transplanted into nonimmunosuppressed diabetic rats are rapidly rejected (20, 21) . In the present study, prolongation ofdiscordant xenograft survival has been achieved in diabetic rats using artificial permselective membranes. Tubular membranes containing canine, bovine, or porcine islets routinely normalized fasting plasma glucose levels after transplantation into streptozotocin-induced diabetic rats. All of the grafts functioned for 1 month, and for at least 10 weeks in bovine and porcine islet xenograft recipients.** In comparison, nonencapsulated islet transplants sustained euglycemia for <1 week.
Although prolongation of survival of islets from discordant species has been achieved by microencapsulation, these studies have been performed mainly in mice and have usually required adjunctive treatment with immunosuppressive agents A (22) (23) (24) . Weber et al. (8) found that alginate/poly(lysine) microcapsules containing 4 x 103 to 1.2 x 104 canine isletstt functioned for only 11.5 + 3 days (range, 5-17 days) in nonobese diabetic mice. With anti-CD4 monoclonal antibody treatment, however, long-term functional survival was observed for 4/8 (50%) recipients. Histologic examination of the microcapsules at the time ofrejection revealed the presence of macrophages, multinucleate giant cells, granulocytes, and lymphocytes, consistent with an inflammatory reaction. It is likely that, once recruited to the surroundings of the microcapsule, lymphokine-secreting cells injured the xenogeneic islets via soluble factors. This is in keeping with reports that the microcapsule membrane is permeable to the immunomodulatory polypeptide products of lymphocytes, macrophages/ monocytes, and natural killer cells of the immune system (2, 25) and that anumber ofcytokines (interferon 'yand interleukin 2) and monokines (interleukin 1 and tumor necrosis factor) induce the degeneration of islet cells (26) (27) (28) .
Recently, Zekorn et al. (29) have shown that rat islets are protected from interleukin 1 toxicity by hollow fiber membranes. A high dose of recombinant human interleukin 1(3 resulted in an inhibition of the glucose-stimulated insulin release of free islets, whereas encapsulated islets showed a preserved insulin release. Therefore, the use of hollow fiber and tubular membrane devices might have potential advantages, especially when engraftment is carried out across a wide species barrier. Indeed, Altman et al. (30) reported that intraperitoneal transplants of human islets and human insulinoma tissue into nonobese diabetic mice had a survival time of <2 weeks, and the survival was increased to >6 months (two-thirds of the animals in each group) when encapsulated in hollow fiber membranes. However, this type of fiber was observed to elicit an inflammatory pericapsular response in the rat (30, 31) and the large-animal (porcine) model (32) . The fibrotic reaction in the rats was qualitatively similar to that seen in the pig, except for lymphoid clusters with giant and pseudo-epithelioid cells that were observed only in pigs. The reaction consisted of a layer (<50 um) of fibroblasts and collagen with polymorphonuclear leucocytes, macrophages, histiocytes, and small lymphocytes. The fiber wall was always infiltrated by collagen, fibroblasts, and macrophages.
Experiments performed in our laboratory corroborate these findings. We compared the use of tubular diffusion chambers with a smooth skin versus a rough skin-i.e., an open trabecular or honeycombed surface-on the outside surface. Membranes with rough external surfaces elicited a significant fibrotic response in streptozotocin-induced diabetic rats in <1 week. In contrast, smooth membranes retrieved >10 weeks after implantation showed no evidence of an inflammatory response. The external membrane surfaces were generally free of fibrotic encapsulation and exhibited only occasional host-cell adherence (Fig. 8) . The response was not influenced by seeding or nonseeding of the chambers or by the type of tissue inside (canine, bovine, or porcine islets). Protection of the xenogeneic tissue by the membrane is demonstrated by the preservation of the structure of the islets residing for >6 months in the peritoneal cavity (Fig. 9) as well as by the presence of hormoneproducing cells containing varying degrees of a, (3, and 8 granulation. Occasionally the chambers were broken or ex- ttAlthough hyperglycemia in rodents has been reversed by interportal or subrenal capsule transplantation using fewer islets, these studies have been performed mainly with free, nonencapsulated islets. Dose-response curves performed in our laboratory using encapsulated islets indicate that larger numbers of islets are necessary to achieve long-term normoglycemia in the large-animalto-rodent encapsulated islet xenograft model. hibited bends that resulted in fracture of the external and internal membrane walls. Such complete fractures permitted xenograft rejection within the interior characterized by the presence of fibroproliferative connective tissue and immune cell elements. Islet cell survival within the alginate matrix was markedly reduced within these damaged membranes.
Although our results with survival of islet xenografts in streptozotocin-induced rats are encouraging, it will be important to utilize this encapsulation technology in spontaneously diabetic animals such as BB rats or nonobese diabetic mice in which diabetes is believed to result from autoimmune ,B-cell damage. Preliminary experiments in diabetic BB/Wor rats suggest that canine islet implants can restore euglycemia for >150 days without immunosuppression. In addition, this should eliminate the possibility of (-cell regeneration that has been reported for the streptozotocin model of diabetes (33) . In related studies in our laboratory we have also observed that removal of islet implants after periods of several weeks did not always result in subsequent large rises in plasma glucose concentrations.
Our results demonstrate the feasibility of long-term immunoisolation of discordant islet xenografts by artificial membranes and the long-term biocompatibility of the membrane versus the graft and versus the recipient. However, to function as an implantable biohybrid artificial pancreas, it is necessary that the islets placed in the device respond appropriately to glucose within a time frame compatible with closed-loop insulin delivery, which requires a response time of <15 min (34, 35) ; pharmacokinetic modeling of glucose homeostasis in man suggests that the lag time of the increase in insulin delivery by an artificial pancreas must be shorter than this to avoid the overexcursion of postprandial blood glucose (35) . Indeed, the increase in insulin release in vitro in response to glucose from perifused macroencapsulated islets was delayed by only 7 min in comparison to nonencapsulated islets. Furthermore, glucose clearance during intravenous FIG. 9 . Encapsulated canine islets retrieved from the peritoneal cavity of a diabetic rat 220 days after xenotransplantation. (Hematoxylin/eosin; x270.) Note the smooth skin on the external surface (arrowheads) versus the rough-i.e., the open trabecular or honeycombed surface-on the luminal side.
glucose tolerance testing was also not delayed. Since there is increasing evidence that the incidence and severity of the microvascular complications of diabetes are linked to the degree of metabolic control attained, the ability of the encapsulated islets to achieve rapid glucose-insulin kinetics may have important implications in assessing the potential role for this type of diff-usion-based biohybrid artificial pancreas as therapy for human insulin-dependent diabetes.
